161 related articles for article (PubMed ID: 9927037)
41. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Lee JW; Soung YH; Kim SY; Lee HW; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Oncogene; 2005 Feb; 24(8):1477-80. PubMed ID: 15608678
[TBL] [Abstract][Full Text] [Related]
42. P53 codon 249 mutation in hepatocellular carcinomas from Nigeria.
Ndububa DA; Yakicier CM; Ojo OS; Adeodu OO; Rotimi O; Ogunbiyi O; Ozturk M
Afr J Med Med Sci; 2001; 30(1-2):125-7. PubMed ID: 14510167
[TBL] [Abstract][Full Text] [Related]
43. Abnormal nucleotide repeat sequence in the TGF-betaRII gene in hepatocellular carcinoma and in uninvolved liver tissue.
Enomoto A; Esumi M; Yamashita K; Takagi K; Takano S; Iwai S
J Pathol; 2001 Oct; 195(3):349-54. PubMed ID: 11673833
[TBL] [Abstract][Full Text] [Related]
44. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
[TBL] [Abstract][Full Text] [Related]
45. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
46. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
[TBL] [Abstract][Full Text] [Related]
47. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma.
Song J; Kim CJ; Cho YG; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
J Gastroenterol Hepatol; 2006 Aug; 21(8):1286-9. PubMed ID: 16872311
[TBL] [Abstract][Full Text] [Related]
48. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas.
Ito T; Nishida N; Fukuda Y; Nishimura T; Komeda T; Nakao K
J Gastroenterol; 2004; 39(4):355-61. PubMed ID: 15168247
[TBL] [Abstract][Full Text] [Related]
49. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
[TBL] [Abstract][Full Text] [Related]
50. bcl 10 gene mutation in hepatocellular carcinoma.
Cheng J; Leng X; Cai S; Cao Z; Cao G; Peng J; Wang S; Du R
Chin Med J (Engl); 2001 Jul; 114(7):747-51. PubMed ID: 11780342
[TBL] [Abstract][Full Text] [Related]
51. c-met mRNA overexpression in human hepatocellular carcinoma.
Boix L; Rosa JL; Ventura F; Castells A; Bruix J; Rodés J; Bartrons R
Hepatology; 1994 Jan; 19(1):88-91. PubMed ID: 8276372
[TBL] [Abstract][Full Text] [Related]
52. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma.
Yoo NJ; Kim YR; Lee SH
Acta Oncol; 2012 Jan; 51(1):107-11. PubMed ID: 21736506
[TBL] [Abstract][Full Text] [Related]
53. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
Schmidt L; Junker K; Weirich G; Glenn G; Choyke P; Lubensky I; Zhuang Z; Jeffers M; Vande Woude G; Neumann H; Walther M; Linehan WM; Zbar B
Cancer Res; 1998 Apr; 58(8):1719-22. PubMed ID: 9563489
[TBL] [Abstract][Full Text] [Related]
54. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma.
Yeh SH; Chiu CM; Chen CL; Lu SF; Hsu HC; Chen DS; Chen PJ
Int J Cancer; 2007 Apr; 120(8):1610-7. PubMed ID: 17230529
[TBL] [Abstract][Full Text] [Related]
55. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma.
Tabor E
J Med Virol; 1994 Apr; 42(4):357-65. PubMed ID: 8046425
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*.
Tanyi J; Tory K; Rigó J; Nagy B; Papp Z
Pathol Oncol Res; 1999; 5(3):187-91. PubMed ID: 10491015
[TBL] [Abstract][Full Text] [Related]
57. Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma.
Noguchi O; Enomoto N; Ikeda T; Kobayashi F; Marumo F; Sato C
J Hepatol; 1996 Mar; 24(3):286-92. PubMed ID: 8778194
[TBL] [Abstract][Full Text] [Related]
58. MET mutations in cancers of unknown primary origin (CUPs).
Stella GM; Benvenuti S; Gramaglia D; Scarpa A; Tomezzoli A; Cassoni P; Senetta R; Venesio T; Pozzi E; Bardelli A; Comoglio PM
Hum Mutat; 2011 Jan; 32(1):44-50. PubMed ID: 20949619
[TBL] [Abstract][Full Text] [Related]
59. The role of signaling pathways in the development and treatment of hepatocellular carcinoma.
Whittaker S; Marais R; Zhu AX
Oncogene; 2010 Sep; 29(36):4989-5005. PubMed ID: 20639898
[TBL] [Abstract][Full Text] [Related]
60. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma.
Woo HG; Kim SS; Cho H; Kwon SM; Cho HJ; Ahn SJ; Park ES; Lee JS; Cho SW; Cheong JY
PLoS One; 2014; 9(12):e115152. PubMed ID: 25521761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
